Are GLP-1s the First Longevity Drugs? Exploring Their Potential Beyond Metabolic Conditions

What's new

Pharmaceutical companies, including Novo Nordisk and Eli Lilly, are increasingly exploring the potential of GLP-1 receptor agonists (GLP-1s) as the first true longevity drugs. While already highly effective for obesity and type 2 diabetes, these medications are showing promise in mitigating a range of age-related comorbidities, from cardiovascular issues to kidney and liver diseases, and even potentially neurodegenerative conditions like Alzheimer's [1].

This marks a significant shift in the pharmaceutical industry towards developing drugs that can broadly impact multiple pathological processes associated with aging, rather than just treating individual diseases. The discussion around GLP-1s as longevity agents gained significant traction at the August Aging Research and Drug Discovery meeting, highlighting a future where early screening and long-acting therapies could prevent chronic diseases before they manifest [1].

The science behind it

Aging is recognized as the primary risk factor for numerous late-life diseases, including heart disease, stroke, cancer, and Alzheimer's. Research over decades has established a scientific foundation for understanding aging, identifying conserved molecular pathways and hallmarks of aging, such as genetic damage, mitochondrial dysfunction, and cellular senescence [1]. These hallmarks are interconnected and contribute to a gradual systemic decline. The concept of 'longevity drugs' aims to target these underlying aging pathways to prevent or treat multiple age-related diseases, thereby extending 'healthspan'—the period of life spent in good health—rather than just lifespan [1].

GLP-1s have demonstrated efficacy beyond their primary metabolic indications. For individuals with obesity or type 2 diabetes, clinical trials and real-world data indicate that GLP-1s improve cardiovascular outcomes and reduce all-cause mortality. Interestingly, a significant portion of these cardiovascular benefits appear to be independent of weight loss, suggesting other mechanisms at play, such as anti-inflammatory effects [1]. These broader effects hint at the drugs' potential to influence multiple aging pathways. While the US FDA does not currently recognize aging as a disease, and thus lacks a regulatory pathway for anti-aging interventions, the accumulating evidence for GLP-1s in various age-related conditions is pushing the boundaries of this definition [1].

What it means in practice

If GLP-1s prove to be effective longevity drugs, they could revolutionize preventive medicine. Instead of waiting for age-related diseases to develop, these medications could be used to proactively mitigate the risk of multiple conditions simultaneously. This approach aligns with the concept of improving healthspan, allowing individuals to live healthier, more vital lives for longer [1].

Currently, clinical trials are underway to assess GLP-1s in conditions beyond obesity and type 2 diabetes, including early-stage Alzheimer's disease. Positive results from these trials, especially in individuals without diabetes, would strongly support the idea that GLP-1s have broad, pan-aging effects. However, for GLP-1s to truly succeed as longevity drugs, they would need to be safe and effective over decades, affordable, and ideally long-acting, potentially leveraging precision medicine approaches [1]. Adherence is a critical factor for preventive medicines, as patients may discontinue treatment due to side effects or cost, particularly if they don't feel an immediate benefit [1].

Caveats

While the potential of GLP-1s as longevity drugs is promising, several caveats remain. The current evidence for broader benefits largely comes from individuals already at high risk due to obesity or type 2 diabetes. The generalizability of these effects to healthy populations, or those with lower risk factors, is not yet established, and clinical data for such groups are lacking [1]. Detecting efficacy in lower-risk individuals would require larger and longer trials, and at some point, the risk-benefit ratio might become too marginal to pursue [1].

Furthermore, the long-term effects of GLP-1s, particularly over many decades, are still unknown. The high discontinuation rates observed in current GLP-1 users due to side effects and cost also pose a challenge for their adoption as long-term preventive therapies [1]. The regulatory landscape also needs to evolve, as aging is not currently recognized as a disease by bodies like the FDA, which complicates the approval pathway for drugs specifically targeting longevity [1].

Source: [1] https://www.nature.com/articles/s41587-025-02932-1